Experimental CAR-T therapy targets tough T-Cell cancers
NCT ID NCT07350863
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study tests a new treatment called U69, which uses a patient's own immune cells modified to find and attack cancer cells in T-cell leukemia or lymphoma that has come back or not responded to other treatments. About 12 to 18 people aged 15 to 75 will receive the therapy to see if it is safe and to find the best dose. The study will also look at how well the treatment controls the cancer over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- U69 (CXCR4 CCR9 CAR-T cells)
- What this could lead to
- If it works, this could point toward a new treatment option for people with hard-to-treat T-cell leukemia or lymphoma.
- What could go wrong
- This is a very early, small Phase 1 trial with only 12-18 people. It mainly checks safety, not effectiveness. Side effects like cytokine release syndrome are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY T-LYMPHOBLASTIC LEUKEMIA/LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215006, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.